• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    MeiraGTx Holdings plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/17/25 8:08:30 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGTX alert in real time by email
    0001735438false00017354382025-06-122025-06-12

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    Current Report Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 12, 2025

    MeiraGTx Holdings plc

    (Exact name of registrant as specified in its charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Cayman Islands

        

    001-38520

        

    98-1448305

    (State or other jurisdiction of incorporation or organization)

     

    (Commission File Number)

     

    (I.R.S. Employer Identification No.)

    ​

    450 East 29th Street, 14th Floor

    New York, NY 10016

    (Address of principal executive offices) (Zip code)

    ​

    (646) 860-7985

    (Registrant’s telephone number, including area code)

    Not applicable

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

        

    Trading
    Symbol(s)

        

    Name of each exchange
    on which registered

    Ordinary Shares, $0.00003881 par
    value per share

     

    MGTX

     

    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company  ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

    ​

    ​

    ​

    ​

    ​

    ​

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    ​

    On June 12, 2025, MeiraGTx Holdings plc (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”). A total of 59,311,935 of the Company’s ordinary shares were present in person or represented by proxy at the Annual Meeting, representing approximately 74.2% of the Company’s ordinary shares outstanding as of the April 14, 2025 record date. Following are the voting results for the proposals considered and voted upon at the Annual Meeting, each of which were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 30, 2025.

    Item 1 – Election of one Class I director to hold office until the Company’s annual general meeting of shareholders to be held in 2028 and until his successor has been duly elected and qualified.

    ​

        

    FOR

        

    WITHHELD

        

    BROKER NON-VOTES

     

    Thomas E. Shenk, Ph.D.

    ​

    40,330,324

    ​

    9,063,978

    ​

    9,917,633

    ​

    ​

    Item 2 – Ratification, by ordinary resolution, of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    FOR

        

    AGAINST

        

    ABSTAINED

     

    45,403,500

    ​

    13,874,350

    ​

    34,085

    ​

    ​

    Based on the above voting results, the director nominee named above was elected and Item 2 was approved.

    ​

    ​

    2

    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    Date: June 17, 2025

    ​

    ​

    ​

    ​

    MEIRAGTX HOLDINGS PLC

    ​

    ​

    ​

    ​

    ​

    By:

    /s/ Richard Giroux

    ​

    Name:

    Richard Giroux

    ​

    Title:

    Chief Financial Officer and Chief Operating Officer

    ​

    ​

    ​

    3

    Get the next $MGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGTX

    DatePrice TargetRatingAnalyst
    7/31/2024$36.00Buy
    Chardan Capital Markets
    More analyst ratings

    $MGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      8/14/24 6:54:38 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Yu Debra

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      6/16/25 9:15:07 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shenk Thomas E

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      6/16/25 9:13:55 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Seligman Nicole

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      6/16/25 9:12:17 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

      LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, which is being held from May 13-17, 2025, in New Orleans, LA. The posters will be available on the Posters and Publications page of the Company's website. The details of the poster presentations are below: Poster 507: An Ultra-Low Dose of a Localized CNS Gene Therapy for Severe Pediatric ObesityPoster Session: Tuesday, May 13, 6:00-7:30 pm CDTAbstract:Brain-derived neurotrophic factor (BDN

      5/13/25 4:30:00 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Reports First Quarter 2025 Financial and Operational Results

      -  Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson's disease -  U.S. Food and Drug Administration (FDA) Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson's disease -  Gained alignment with FDA on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential BL

      5/13/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

      -  This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease -  RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV-GAD for the t

      5/9/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    SEC Filings

    See more
    • MeiraGTx Holdings plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MeiraGTx Holdings plc (0001735438) (Filer)

      6/17/25 8:08:30 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by MeiraGTx Holdings plc

      SCHEDULE 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      5/14/25 8:30:35 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by MeiraGTx Holdings plc

      10-Q - MeiraGTx Holdings plc (0001735438) (Filer)

      5/13/25 8:09:19 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care